Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Influenza

  Free Subscription


Articles published in J Exp Med

Retrieve available abstracts of 66 articles:
HTML format



Single Articles


    August 2022
  1. ZHANG Q, Matuozzo D, Le Pen J, Lee D, et al
    Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia.
    J Exp Med. 2022;219.
    PubMed     Abstract available


    July 2022
  2. WARE CF, Croft M, Neil GA
    Realigning the LIGHT signaling network to control dysregulated inflammation.
    J Exp Med. 2022;219.
    PubMed     Abstract available


  3. CAMPBELL TM, Liu Z, Zhang Q, Moncada-Velez M, et al
    Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency.
    J Exp Med. 2022;219.
    PubMed     Abstract available


  4. PLANCHAIS C, Fernandez I, Bruel T, de Melo GD, et al
    Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
    J Exp Med. 2022;219.
    PubMed     Abstract available


    June 2022
  5. DUNCAN CJA, Skouboe MK, Howarth S, Hollensen AK, et al
    Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic.
    J Exp Med. 2022;219.
    PubMed     Abstract available


  6. CASTLEMAN MJ, Stumpf MM, Therrien NR, Smith MJ, et al
    SARS-CoV-2 infection relaxes peripheral B cell tolerance.
    J Exp Med. 2022;219.
    PubMed     Abstract available


  7. MEYTS I
    Null IFNAR1 and IFNAR2 alleles are surprisingly common in the Pacific and Arctic.
    J Exp Med. 2022;219.
    PubMed     Abstract available


    April 2022
  8. PUEL A, Bastard P, Bustamante J, Casanova JL, et al
    Human autoantibodies underlying infectious diseases.
    J Exp Med. 2022;219.
    PubMed     Abstract available


    February 2022
  9. ZHANG B, Zhang Y, Xiong L, Li Y, et al
    CD127 imprints functional heterogeneity to diversify monocyte responses in inflammatory diseases.
    J Exp Med. 2022;219.
    PubMed     Abstract available


  10. HOSTE L, Roels L, Naesens L, Bosteels V, et al
    TIM3+ TRBV11-2 T cells and IFNgamma signature in patrolling monocytes and CD16+ NK cells delineate MIS-C.
    J Exp Med. 2022;219.
    PubMed     Abstract available


  11. HILLIGAN KL, Namasivayam S, Clancy CS, O'Mard D, et al
    Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge.
    J Exp Med. 2022;219.
    PubMed     Abstract available


    January 2022
  12. MAO T, Israelow B, Lucas C, Vogels CBF, et al
    A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice.
    J Exp Med. 2022;219.
    PubMed     Abstract available


    December 2021
  13. SHINNAKASU R, Sakakibara S, Yamamoto H, Wang PH, et al
    Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  14. LU X, Hosono Y, Nagae M, Ishizuka S, et al
    Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  15. PYLE CJ, Labeur-Iurman L, Groves HT, Puttur F, et al
    Enhanced IL-2 in early life limits the development of TFH and protective antiviral immunity.
    J Exp Med. 2021;218.
    PubMed     Abstract available


    November 2021
  16. RAPPE JCF, Finsterbusch K, Crotta S, Mack M, et al
    A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  17. FONSECA W, Malinczak CA, Fujimura K, Li D, et al
    Maternal gut microbiome regulates immunity to RSV infection in offspring.
    J Exp Med. 2021;218.
    PubMed     Abstract available


    October 2021
  18. DECKER T
    The early interferon catches the SARS-CoV-2.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  19. LOPEZ J, Mommert M, Mouton W, Pizzorno A, et al
    Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.
    J Exp Med. 2021;218.
    PubMed     Abstract available


    September 2021
  20. AHN M, Wang LF
    Translation from bats to humans beyond infectious diseases.
    J Exp Med. 2021;218.
    PubMed     Abstract available


    August 2021
  21. CHEEMARLA NR, Watkins TA, Mihaylova VT, Wang B, et al
    Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  22. WILK AJ, Lee MJ, Wei B, Parks B, et al
    Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19.
    J Exp Med. 2021;218.
    PubMed     Abstract available


    July 2021
  23. BASTARD P, Orlova E, Sozaeva L, Levy R, et al
    Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  24. SOLFOROSI L, Kuipers H, Jongeneelen M, Rosendahl Huber SK, et al
    Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
    J Exp Med. 2021;218.
    PubMed     Abstract available


    June 2021
  25. LANZ C, Schotsaert M, Magnus C, Karakus U, et al
    IFITM3 incorporation sensitizes influenza A virus to antibody-mediated neutralization.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  26. SANCHO-SHIMIZU V, Brodin P, Cobat A, Biggs CM, et al
    SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease?
    J Exp Med. 2021;218.
    PubMed     Abstract available


    May 2021
  27. ANDREANO E, Rappuoli R
    Immunodominant antibody germlines in COVID-19.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  28. LE BERT N, Clapham HE, Tan AT, Chia WN, et al
    Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  29. MERAD M, Vabret N
    Highlights from a year in a pandemic.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  30. BAUM A, Kyratsous CA
    SARS-CoV-2 spike therapeutic antibodies in the age of variants.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  31. KEDL RM
    Down but far from out: The durability of SARS-CoV-2 immunity after asymptomatic infection.
    J Exp Med. 2021;218.
    PubMed     Abstract available


    April 2021
  32. ZHUANG Z, Lai X, Sun J, Chen Z, et al
    Mapping and role of T cell response in SARS-CoV-2-infected mice.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  33. ONODI F, Bonnet-Madin L, Meertens L, Karpf L, et al
    SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  34. BRETON G, Mendoza P, Hagglof T, Oliveira TY, et al
    Persistent cellular immunity to SARS-CoV-2 infection.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  35. BASTARD P, Michailidis E, Hoffmann HH, Chbihi M, et al
    Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  36. POON MML, Farber DL
    Lasting memories of SARS-CoV-2 infection.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  37. MCCARTY NA
    Breathe-Your immune system is counting on it.
    J Exp Med. 2021;218.
    PubMed     Abstract available


    March 2021
  38. SCHAFER A, Muecksch F, Lorenzi JCC, Leist SR, et al
    Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  39. LU Y, Jiang R, Freyn AW, Wang J, et al
    CD4+ follicular regulatory T cells optimize the influenza virus-specific B cell response.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  40. RODRIGUES TS, de Sa KSG, Ishimoto AY, Becerra A, et al
    Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  41. BRYANT C
    COVID-19 stokes inflammasomes.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  42. SONG E, Zhang C, Israelow B, Lu-Culligan A, et al
    Neuroinvasion of SARS-CoV-2 in human and mouse brain.
    J Exp Med. 2021;218.
    PubMed     Abstract available


  43. NIMMERJAHN F, Ravetch JV
    Four keys to unlock IgG.
    J Exp Med. 2021;218.
    PubMed     Abstract available


    January 2021
  44. PAIK DH, Farber DL
    Influenza infection fortifies local lymph nodes to promote lung-resident heterosubtypic immunity.
    J Exp Med. 2021;218.
    PubMed     Abstract available


    December 2020
  45. ISRAELOW B, Song E, Mao T, Lu P, et al
    Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  46. JOUAN Y, Guillon A, Gonzalez L, Perez Y, et al
    Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  47. VERAS FP, Pontelli MC, Silva CM, Toller-Kawahisa JE, et al
    SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  48. RADERMECKER C, Detrembleur N, Guiot J, Cavalier E, et al
    Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  49. MAJOR J, Wack A
    An ace model for SARS-CoV-2 infection.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  50. KOAY HF, Fulford TS, Godfrey DI
    An unconventional view of COVID-19 T cell immunity.
    J Exp Med. 2020;217.
    PubMed     Abstract available


    November 2020
  51. SCHMIDT F, Weisblum Y, Muecksch F, Hoffmann HH, et al
    Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  52. SHUBINA M, Tummers B, Boyd DF, Zhang T, et al
    Necroptosis restricts influenza A virus as a stand-alone cell death mechanism.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  53. KIM JH
    SARS-CoV-2 vaccine development, access, and equity.
    J Exp Med. 2020;217.
    PubMed     Abstract available


    October 2020
  54. CASSOTTA A, Paparoditis P, Geiger R, Mettu RR, et al
    Deciphering and predicting CD4+ T cell immunodominance of influenza virus hemagglutinin.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  55. ZHOU T, Su TT, Mudianto T, Wang J, et al
    Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies.
    J Exp Med. 2020;217.
    PubMed     Abstract available


    September 2020
  56. KOENIG LM, Boehmer DFR, Metzger P, Schnurr M, et al
    Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  57. NATHAN C
    Neutrophils and COVID-19: Nots, NETs, and knots.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  58. FREEDMAN TS, Headley MB, Serwas N, Ruhland M, et al
    Lessons of COVID-19: A roadmap for post-pandemic science.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  59. HOUSTON S
    Lessons of COVID-19: Virtual conferences.
    J Exp Med. 2020;217.
    PubMed     Abstract available


    August 2020
  60. STOLLEY JM, Johnston TS, Soerens AG, Beura LK, et al
    Retrograde migration supplies resident memory T cells to lung-draining LN after influenza infection.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  61. DIAMOND B
    The renin-angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications.
    J Exp Med. 2020;217.
    PubMed     Abstract available


    June 2020
  62. BARNES BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, et al
    Targeting potential drivers of COVID-19: Neutrophil extracellular traps.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  63. VARDHANA SA, Wolchok JD
    The many faces of the anti-COVID immune response.
    J Exp Med. 2020;217.
    PubMed     Abstract available


    May 2020
  64. NATHAN CF, Nussenzweig MC, Pulvirenti T
    We are here for you and ready to hear from you.
    J Exp Med. 2020;217.
    PubMed    


  65. WEISS SR
    Forty years with coronaviruses.
    J Exp Med. 2020;217.
    PubMed     Abstract available


  66. PROKUNINA-OLSSON L, Alphonse N, Dickenson RE, Durbin JE, et al
    COVID-19 and emerging viral infections: The case for interferon lambda.
    J Exp Med. 2020;217.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: